{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2024.05.30.24308216v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2024.05.30.24308216v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2024.05.30.24308216v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cp id=\u0022p-2\u0022\u003EADHD is a chronic neurodevelopmental disorder which significantly affects life outcomes. First-line treatments carry the risk of adverse side effects and present a high abuse potential, coupled with a 25% rate of non-response, necessitating novel treatments. Here, we validate amlodipine as an ADHD treatment using model rats and zebrafish and human genetic data. Amlodipine reduced hyperactivity in the Open Field Test in SHR rats and reduced both hyperactivity and impulsivity in the 5-Choice Serial Reaction Time Task in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Ezebrafish. We show that amlodipine also passes the blood brain barrier and reduces telencephalic activation. Mendelian Randomization analysis using human genetic data revealed significant associations between ADHD and genetic variations in the subunits of L-type calcium channels (\u03b11-C; CACNA1C, \u03b21; CACNB1, \u03b12\u03b43; CACNA2D3), and the combined genes targeted by amlodipine. Finally, we show that amlodipine mitigates key ADHD symptoms in a cohort of people with a high ADHD genetic liability. Given its well-tolerated profile, its efficacy in mitigating both hyperactivity and impulsivity across different species, coupled with genetic evidence from human data, the potential utility of amlodipine as a novel treatment for human ADHD is compelling.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EIntroduction\u003C\/h2\u003E\u003Cp id=\u0022p-15\u0022\u003EAttention-deficit\/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition impacting 2-5% of the global population.\u003Csup\u003E\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E\u003C\/sup\u003E Symptoms typically emerge in early childhood and persist into adulthood, leading to a range of behavioral and psychiatric challenges.\u003Csup\u003E\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u003C\/sup\u003E Left untreated, ADHD is associated with functional impairments, heightened risk of mood and anxiety disorders, and severe consequences, including an increased risk of suicide.\u003Csup\u003E\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E The primary treatment for ADHD involves stimulant medications like methylphenidate and d-amphetamines. However, these medications come with side effects such as appetite loss, hypertension, headaches, and sleep disturbances, as well as high abuse liability.\u003Csup\u003E\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E\u003C\/sup\u003E Second-line options also carry adverse effects, provide less efficacy than stimulants, and around 25% of patients show no significant improvement from any therapeutic.\u003Csup\u003E\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E Thus, there is an urgent need for more innovative and effective ADHD therapeutics.\u003C\/p\u003E\u003Cp id=\u0022p-16\u0022\u003EWe previously identified five compounds with the potential to be repurposed for ADHD treatment: aceclofenac, amlodipine, doxazosin, moxonidine, and LNP599.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E Here, our aim was to investigate the potential for these previously identified compounds to be adopted as viable ADHD therapeutics. Towards this aim, first, we determined the efficacy in a mammalian ADHD model, using an Open Field Test (OFT) in the Spontaneously Hypertensive Rat (SHR).\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E Second, we determined if the compounds are effective for rescuing impulsivity (not only hyperactivity) using the 5-Choice Serial Reaction Time Task (5-CSRTT) in adult mutant zebrafish.\u003Csup\u003E\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E We show effects of other L-type calcium channel blockers (LTCCBs), determine brain penetration and effects on c-Fos expression. Finally, we determine human translational value using Mendelian randomization (MR)\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/sup\u003E and by assessing the effect of amlodipine on mental health questionnaire responses associated with high ADHD polygenic risk scores (PRS).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EResults\u003C\/h2\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAmlodipine affects Open Field Behavior in SHR rats\u003C\/h3\u003E\u003Cp id=\u0022p-17\u0022\u003ETo assess the therapeutic effects of amlodipine on ADHD, we examined its effects on the gold standard rodent ADHD assay. Eight groups were used: seven SHR groups, each group receiving a different treatment: vehicle control, clonidine (positive control), moxonidine, LNP599, doxazosin, amlodipine, and aceclofenac. A control group of Wistar-Kyoto (WKY) rats received the vehicle control only. Our data show that long-term daily administration (day 0 to day 29) of amlodipine induces significant behavioral changes in SHR rats in the OFT; the effects of all other drugs were non-significant (Supplementary Figure 1) and thus excluded from further analysis. Specifically, amlodipine administration reduced indices of hyperactivity, i.e., distance traveled and ambulatory time (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1A-I\u003C\/a\u003E). No significant differences in rearing time were observed between vehicle-treated and amlodipine-treated female or male SHR rats were observed on either day 0 or day 29 (n.s.) (\u003Ca id=\u0022xref-fig-1-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1A-C\u003C\/a\u003E). For distance traveled, a significant interaction between time and treatment was evident among female rats (\u003Cem\u003EF\u003C\/em\u003E(2,26) = 10.08, \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.001) and when sexes were combined (\u003Cem\u003EF\u003C\/em\u003E(2,56) = 5.222, \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01). No significant interaction was observed among male rats (\u003Cem\u003EF\u003C\/em\u003E(2,27) = 0.2071, \u003Cem\u003Ep\u003C\/em\u003E = 0.8142). At day 29, female amlodipine-treated SHR rats showed reduced distance traveled compared to vehicle-treated SHR female rats (\u003Cem\u003Ep\u003C\/em\u003E = 0.0021) (\u003Ca id=\u0022xref-fig-1-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1D\u003C\/a\u003E). For ambulatory time, a significant difference between vehicle-treated SHR and amlodipine-treated SHR rats (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01) also appeared when pooling the sexes (\u003Ca id=\u0022xref-fig-1-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1F\u003C\/a\u003E). A significant interaction between time and treatment was evident among female rats (\u003Cem\u003EF\u003C\/em\u003E(2, 26) = 17.47, \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001) and when sexes were combined (\u003Cem\u003EF\u003C\/em\u003E(2, 56) = 9.127, \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.001). No significant interaction was observed among male rats (\u003Cem\u003EF\u003C\/em\u003E(2, 27) = 0.3082, \u003Cem\u003Ep\u003C\/em\u003E = 0.7373). At day 29, female amlodipine-treated SHR rats showed reduced ambulatory time compared to vehicle-treated SHR rats (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01) (\u003Ca id=\u0022xref-fig-1-5\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1G\u003C\/a\u003E). Among male rats, significant differences were evident at day 29 between vehicle-treated SHR (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001) and amlodipine-treated SHR rats (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001) (\u003Ca id=\u0022xref-fig-1-6\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1H\u003C\/a\u003E). Similarly, when combining males and females, a significant effect was evident at day 29 between vehicle-treated SHR and amlodipine-treated SHR rats (p \u0026lt; 0.01) (\u003Ca id=\u0022xref-fig-1-7\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1I\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Effect of amlodipine on Open Field Behavior in SHR rats. SHR rats were treated with either amlodipine (10 mg\/kg) or a vehicle daily for 30 days; WKY rats received vehicle only. Assessments were made before treatment (D0) and at end of treatment (D29) using OFT. Measurements included rearing frequency (A, B, C), distance traveled in the center zone (D, E, F), and ambulatory time in the center zone (G, H, I). Reduced distance traveled was revealed at D29, with amlodipine-treated SHR rats covering significantly less distance than vehicle-treated SHR rats in the female group (D) and for both sexes combined (F). Additionally, reduced ambulatory time was observed at D29, where amlodipine-treated SHR rats spent significantly less time ambulating in the center zone compared to vehicle-treated SHR rats in the female group (G) and for both sexes combined (I). Data are depicted as mean \u0026#xB1; SEM, *P \u0026#x2264; 0.05, **P \u0026#x2264; 0.01, ***P \u0026#x2264; 0.001, ****P \u0026#x2264; 0.0001.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2049270684\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Effect of amlodipine on Open Field Behavior in SHR rats.\u0026lt;\/span\u0026gt; SHR rats were treated with either amlodipine (10 mg\/kg) or a vehicle daily for 30 days; WKY rats received vehicle only. Assessments were made before treatment (D0) and at end of treatment (D29) using OFT. Measurements included rearing frequency (A, B, C), distance traveled in the center zone (D, E, F), and ambulatory time in the center zone (G, H, I). Reduced distance traveled was revealed at D29, with amlodipine-treated SHR rats covering significantly less distance than vehicle-treated SHR rats in the female group (D) and for both sexes combined (F). Additionally, reduced ambulatory time was observed at D29, where amlodipine-treated SHR rats spent significantly less time ambulating in the center zone compared to vehicle-treated SHR rats in the female group (G) and for both sexes combined (I). Data are depicted as mean \u0026#xB1; SEM, *\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.05, **\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.01, ***\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.001, ****\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.0001.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022338\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022338\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EEffect of amlodipine on Open Field Behavior in SHR rats.\u003C\/span\u003E\u003Cp id=\u0022p-18\u0022 class=\u0022first-child\u0022\u003ESHR rats were treated with either amlodipine (10 mg\/kg) or a vehicle daily for 30 days; WKY rats received vehicle only. Assessments were made before treatment (D0) and at end of treatment (D29) using OFT. Measurements included rearing frequency (A, B, C), distance traveled in the center zone (D, E, F), and ambulatory time in the center zone (G, H, I). Reduced distance traveled was revealed at D29, with amlodipine-treated SHR rats covering significantly less distance than vehicle-treated SHR rats in the female group (D) and for both sexes combined (F). Additionally, reduced ambulatory time was observed at D29, where amlodipine-treated SHR rats spent significantly less time ambulating in the center zone compared to vehicle-treated SHR rats in the female group (G) and for both sexes combined (I). Data are depicted as mean \u00b1 SEM, *\u003Cem\u003EP\u003C\/em\u003E \u2264 0.05, **\u003Cem\u003EP\u003C\/em\u003E \u2264 0.01, ***\u003Cem\u003EP\u003C\/em\u003E \u2264 0.001, ****\u003Cem\u003EP\u003C\/em\u003E \u2264 0.0001.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-19\u0022\u003EIn summary, there is an effect of amlodipine on distance moved and ambulatory time but not rearing frequency in the OFT. This effect is driven by female rats. Since only amlodipine was effective in modulating the behavior of SHR rats in the OFT, only amlodipine was used in subsequent experiments.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAmlodipine reduces impulsivity in adult \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E zebrafish\u003C\/h3\u003E\u003Cp id=\u0022p-20\u0022\u003EWe have previously shown that zebrafish lacking the adhesion G-protein coupled receptor latrophilin 3 (\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E) show increased hyperactivity in the open field and increased impulsivity in the 5-CSRTT.\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E Like in SHR rats, we previously found that amlodipine effectively rescues hyperactive phenotype in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E zebrafish\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E models of ADHD. Here, we tested the hypothesis that amlodipine would also reduce impulsivity in ADHD zebrafish models in the 5-CSRTT - an assay specifically designed to gauge impulsivity\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E and pharmacologically validated in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E ADHD models.\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E There were no differences in Phase 2 training between wild-type (WT) and \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E (main effect Strain LMM: \u003Cem\u003EF\u003C\/em\u003E[1,297.06] = 0.09, \u003Cem\u003Ep\u003C\/em\u003E = 0.769). During baseline 5-CSRTT Phase 2 (pre-drug treatment), \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Efish showed more premature responses than WT, \u003Cem\u003Et\u003C\/em\u003E(40.45) = 2.02, \u003Cem\u003Ep\u003C\/em\u003E = 0.05, 95%CI = 0 - 0.1 (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2B\u003C\/a\u003E). Drug treatment was initiated following Phase 2. There was a significant main effect of Drug Type (LMM: \u003Cem\u003EF\u003C\/em\u003E [2,16.55] = 3.76, \u003Cem\u003Ep\u003C\/em\u003E = 0.045), with treatment with both amlodipine (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.001) and methylphenidate (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01) causing a reduction in impulsive responses in the \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E fish (\u003Ca id=\u0022xref-fig-2-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2C\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Acute effects of amlodipine and methylphenidate on impulsivity in adult zebrafish. (A) The test tank and schematic overview of the 5-CSRTT. (B) Proportion of premature responses in age matched wild-type and adgrl3.1-\/-adult zebrafish. (C) Effects of amlodipine (10 \u0026#xB5;M) and methylphenidate (10 \u0026#xB5;M) on impulsive responses in adgrl3.1-\/-adult zebrafish. Data are depicted as mean \u0026#xB1; SEM.,*P = 0.05; **P \u0026lt; 0.01.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2049270684\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Acute effects of amlodipine and methylphenidate on impulsivity in adult zebrafish.\u0026lt;\/span\u0026gt; (A) The test tank and schematic overview of the 5-CSRTT. (B) Proportion of premature responses in age matched wild-type and \u0026lt;em\u0026gt;adgrl3.1\u0026lt;sup\u0026gt;-\/-\u0026lt;\/sup\u0026gt;\u0026lt;\/em\u0026gt;adult zebrafish. (C) Effects of amlodipine (10 \u0026#xB5;M) and methylphenidate (10 \u0026#xB5;M) on impulsive responses in \u0026lt;em\u0026gt;adgrl3.1\u0026lt;sup\u0026gt;-\/-\u0026lt;\/sup\u0026gt;\u0026lt;\/em\u0026gt;adult zebrafish. Data are depicted as mean \u0026#xB1; SEM.,*\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; = 0.05; **\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026lt; 0.01.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022260\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022260\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EAcute effects of amlodipine and methylphenidate on impulsivity in adult zebrafish.\u003C\/span\u003E\u003Cp id=\u0022p-21\u0022 class=\u0022first-child\u0022\u003E(A) The test tank and schematic overview of the 5-CSRTT. (B) Proportion of premature responses in age matched wild-type and \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Eadult zebrafish. (C) Effects of amlodipine (10 \u00b5M) and methylphenidate (10 \u00b5M) on impulsive responses in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Eadult zebrafish. Data are depicted as mean \u00b1 SEM.,*\u003Cem\u003EP\u003C\/em\u003E = 0.05; **\u003Cem\u003EP\u003C\/em\u003E \u0026lt; 0.01.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EEffects of additional L-type calcium channel blockers on hyperactivity and sleep in larval \u003Cem\u003Eagdrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E ADHD model\u003C\/h3\u003E\u003Cp id=\u0022p-22\u0022\u003EDue to the efficacy of amlodipine in rescuing hyperactivity and impulsivity in ADHD rodent and zebrafish models, twelve other LTCCBs were assayed in the larval ADHD assay described previously.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E Five LTCCBs (diltiazem, lacidipine, nicardipine, nisoldipine and nitrendipine) did not have any effect on hyperactivity whereas seven (cilnidipine, felodipine, isradipine, nifedipine, nilvadipine, nimodipine and verapamil) did. The effective LTCCBs generated a profile roughly similar to that of amlodipine: that is reduction of hyperactivity with low effects on sleep parameters. However, all drugs except nifedipine and nimodipine were toxic at medium to high doses and induced higher behavioral variability than amlodipine (Supplementary Figure 2).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAmlodipine crosses the blood-brain barrier and affects c-Fos expression\u003C\/h3\u003E\u003Cp id=\u0022p-23\u0022\u003ETo assess the extent to which amlodipine can cross the blood-brain barrier (BBB), and to establish the functional mechanisms by which amlodipine may exert its behavioral effects in the central nervous system, we quantified the concentration of amlodipine in the brain tissue and examined its impact on neuronal activation in the telencephalon. Following exposure to 10 \u00b5M amlodipine (n = 6), whole-brain amlodipine levels in adult \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Efish were measured at 0.013 \u00b1 0.003 ng\/ml; no amlodipine was detected in non-exposed fish (except for one which measured at 9 x 10\u003Csup\u003E-\u003C\/sup\u003E\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E ng\/ml, which we attribute to sample contamination) (n = 6). No sex differences were measured. One-way ANOVA revealed significant differences in c-Fos expression within the telencephalon (\u003Cem\u003EF\u003C\/em\u003E(3,88) = 16.76, \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.0001). \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E and WT larvae subjected to amlodipine treatment showed significant downregulation of c-Fos expression compared to those treated with DMSO (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.05 and \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.01, respectively). These results show, at the dose used to rescue the hyperactive and impulsive phenotype, amlodipine permeates the brain and suppresses c-Fos expression (\u003Ca id=\u0022xref-fig-3-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F3\u0022\u003EFigure 3\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F3\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F3.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022c-Fos expression in adgrl3.1-\/- zebrafish in the telencephalon following amlodipine exposure. (A) A schematic representation of a 6 dpf zebrafish larva, red dashed rectangle within the telencephalon denotes the area used for counting. Representative figures of immunohistochemically labeled c-Fos of adgrl3.1-\/- zebrafish larvae treated with (B) 10 \u0026#xB5;M amlodipine and (C) 0.1% DMSO and WT zebrafish larvae treated with (D) 10 \u0026#xB5;M amlodipine and (E) 0.1% DMSO. (F) c-Fos count for each group. Data are mean \u0026#xB1; SEM, *P \u0026#x2264; 0.05, **P \u0026#x2264; 0.01, (scale bar = 10 \u0026#xB5;m).\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2049270684\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;c-Fos expression in \u0026lt;em\u0026gt;adgrl3.1\u0026lt;sup\u0026gt;-\/-\u0026lt;\/sup\u0026gt;\u0026lt;\/em\u0026gt; zebrafish in the telencephalon following amlodipine exposure.\u0026lt;\/span\u0026gt; (A) A schematic representation of a 6 dpf zebrafish larva, red dashed rectangle within the telencephalon denotes the area used for counting. Representative figures of immunohistochemically labeled c-Fos of \u0026lt;em\u0026gt;adgrl3.1\u0026lt;sup\u0026gt;-\/-\u0026lt;\/sup\u0026gt;\u0026lt;\/em\u0026gt; zebrafish larvae treated with (B) 10 \u0026#xB5;M amlodipine and (C) 0.1% DMSO and WT zebrafish larvae treated with (D) 10 \u0026#xB5;M amlodipine and (E) 0.1% DMSO. (F) c-Fos count for each group. Data are mean \u0026#xB1; SEM, *\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.05, **\u0026lt;em\u0026gt;P\u0026lt;\/em\u0026gt; \u0026#x2264; 0.01, (scale bar = 10 \u0026#xB5;m).\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 3.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022278\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 3.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F3.medium.gif\u0022 width=\u0022440\u0022 height=\u0022278\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F3.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 3.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F3.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 3.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003Ec-Fos expression in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E zebrafish in the telencephalon following amlodipine exposure.\u003C\/span\u003E\u003Cp id=\u0022p-24\u0022 class=\u0022first-child\u0022\u003E(A) A schematic representation of a 6 dpf zebrafish larva, red dashed rectangle within the telencephalon denotes the area used for counting. Representative figures of immunohistochemically labeled c-Fos of \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E zebrafish larvae treated with (B) 10 \u00b5M amlodipine and (C) 0.1% DMSO and WT zebrafish larvae treated with (D) 10 \u00b5M amlodipine and (E) 0.1% DMSO. (F) c-Fos count for each group. Data are mean \u00b1 SEM, *\u003Cem\u003EP\u003C\/em\u003E \u2264 0.05, **\u003Cem\u003EP\u003C\/em\u003E \u2264 0.01, (scale bar = 10 \u00b5m).\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-7\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EGenome-wide Mendelian randomization on hypertension and ADHD\u003C\/h3\u003E\u003Cp id=\u0022p-25\u0022\u003EHaving established the effects of amlodipine on ADHD symptoms across two animal models, and confirmed its ability to cross the BBB and its putative functional effects in the telencephalon, we next employed MR to extend the results from animal studies to human genetic data. We first confirmed the well-established effect of amlodipine on hypertension before exploring the relationship between amlodipine target perturbation and ADHD. First, the causal effect of 140 traits on hypertension and ADHD was estimated using genome-wide MR. The manually curated list of traits includes blood cell counts, metabolites, amino acids, lipids, and enzymes. Three traits with a significant causal effect estimate were found for hypertension (\u003Ca id=\u0022xref-fig-4-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4A\u003C\/a\u003E, Supplementary Table 2): BMI and phenylalanine increased the risk of hypertension, while nucleated erythrocyte percentage decreased it. Three traits with a significant causal effect estimate for ADHD (\u003Ca id=\u0022xref-fig-4-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4B\u003C\/a\u003E, Supplementary Table 2) were identified: sodium in the urine, higher BMI and acetate increased the risk of general ADHD.\u003C\/p\u003E\u003Cdiv id=\u0022F4\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F4.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Genome-wide and drug-target Mendelian Randomization. (A) Only exposures with significant causal effects for hypertension are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective change in log odds ratio for ADHD. (B) Only exposures with significant causal effect estimates for ADHD are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for hypertension. (C) Only exposures which had significant causal effects for hypertension mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective decrease in log odds ratio for hypertension. (D) Only exposures which had significant causal effects for ADHD mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for ADHD.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2049270684\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;Genome-wide and drug-target Mendelian Randomization.\u0026lt;\/span\u0026gt; (A) Only exposures with significant causal effects for hypertension are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; \u0026#x3B1;\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective change in log odds ratio for ADHD. (B) Only exposures with significant causal effect estimates for ADHD are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; \u0026#x3B1;\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for hypertension. (C) Only exposures which had significant causal effects for hypertension mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective decrease in log odds ratio for hypertension. (D) Only exposures which had significant causal effects for ADHD mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u0026#x3B1;\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for ADHD.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 4.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F4.medium.gif\u0022 width=\u0022397\u0022 height=\u0022440\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 4.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F4.medium.gif\u0022 width=\u0022397\u0022 height=\u0022440\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F4.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 4.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F4.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 4.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EGenome-wide and drug-target Mendelian Randomization.\u003C\/span\u003E\u003Cp id=\u0022p-26\u0022 class=\u0022first-child\u0022\u003E(A) Only exposures with significant causal effects for hypertension are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; \u03b1\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective change in log odds ratio for ADHD. (B) Only exposures with significant causal effect estimates for ADHD are shown. The significance threshold was Bonferroni corrected for multiple testing of 140 traits (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; \u03b1\/n = 0.05\/140). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for hypertension. (C) Only exposures which had significant causal effects for hypertension mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u03b1\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective decrease in log odds ratio for hypertension. (D) Only exposures which had significant causal effects for ADHD mediated by one of the eight groups of genes are reported. The significance threshold was Bonferroni corrected for multiple testing of 140 traits and 8 gene selections (p \u0026lt; \u03b1\/n = 0.05\/140\/8). Green dots indicate a significant causal effect without pleiotropy. Estimates are scaled per 1-standard deviation (SD) increase in the respective exposure trait, i. e., every 1-SD higher genetically proxied trait level was associated with the respective increase in log odds ratio for ADHD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDrug-target Mendelian randomization confirms potential for amlodipine to target ADHD symptoms\u003C\/h3\u003E\u003Cp id=\u0022p-27\u0022\u003EAmlodipine inhibits the voltage-dependent calcium channels of type L (subunits \u03b1\u003Csub\u003E1\u003C\/sub\u003E-C and \u03b2\u003Csub\u003E1\u003C\/sub\u003E, encoded by \u003Cem\u003ECACNA1C\u003C\/em\u003E and \u003Cem\u003ECACNB1\u003C\/em\u003E, respectively), type T (subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-I, \u003Cem\u003ECACNA1I\u003C\/em\u003E), type N (subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-B, \u003Cem\u003ECACNA1B\u003C\/em\u003E) and auxiliary subunit \u03b1\u003Csub\u003E2\u003C\/sub\u003E\u03b4\u003Csub\u003E3\u003C\/sub\u003E (\u003Cem\u003ECACNA2D3\u003C\/em\u003E). In addition to calcium channels, amlodipine inhibits Carbonic anhydrase 1 (\u003Cem\u003ECA1\u003C\/em\u003E) and Sphingomyelin phosphodiesterase (\u003Cem\u003ESMPD1\u003C\/em\u003E), according to Drugbank online (\u003Ca href=\u0022https:\/\/go.drugbank.com\/drugs\/DB00381\u0022\u003Ehttps:\/\/go.drugbank.com\/drugs\/DB00381\u003C\/a\u003E). To investigate the potential effect of amlodipine on ADHD, the instrumental variables for the MR experiments were drawn only from the seven genes that code for the protein targets of amlodipine (drug-target MR). Eight groups of experiments were conducted: drawing genetic variants from the genes of all amlodipine drug targets combined and the genes of the seven individual drug targets. The same selection of exposures was screened.\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003EFirst, the known effect of amlodipine on hypertension was reconfirmed using our new method: significant effects on hypertension were caused by the variance in the genes encoding for the \u03b1\u003Csub\u003E1\u003C\/sub\u003E subunits of all three calcium channel subtypes (L-type subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-C, \u003Cem\u003ECACNA1C\u003C\/em\u003E; T-type subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-I, \u003Cem\u003ECACNA1I\u003C\/em\u003E; N-type subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-B, \u003Cem\u003ECACNA1B\u003C\/em\u003E) and by all amlodipine target genes combined (\u003Ca id=\u0022xref-fig-4-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4C\u003C\/a\u003E, Supplementary Table 3). In all cases, these effects were mediated by a unique trait. No significant effect was observed when using gene variants from \u003Cem\u003ECACNB1\u003C\/em\u003E, \u003Cem\u003ECACNA2D3\u003C\/em\u003E, \u003Cem\u003ECA1\u003C\/em\u003E, or \u003Cem\u003ESMPD1\u003C\/em\u003E. Interestingly, significant effects on ADHD were caused by the variance in the genes encoding for the three tested subunits of L-type calcium channels (subunits \u03b1\u003Csub\u003E1\u003C\/sub\u003E-C \u003Cem\u003ECACNA1C\u003C\/em\u003E; \u03b2\u003Csub\u003E1\u003C\/sub\u003E, \u003Cem\u003ECACNB1\u003C\/em\u003E; \u03b1\u003Csub\u003E2\u003C\/sub\u003E\u03b4\u003Csub\u003E3\u003C\/sub\u003E, \u003Cem\u003ECACNA2D3\u003C\/em\u003E) and by all amlodipine target genes combined (\u003Ca id=\u0022xref-fig-4-4\u0022 class=\u0022xref-fig\u0022 href=\u0022#F4\u0022\u003EFigure 4D\u003C\/a\u003E, Supplementary Table 4). No significant effect was observed when using gene variants from \u003Cem\u003ECACNA1B\u003C\/em\u003E, \u003Cem\u003ECACNA1I\u003C\/em\u003E, \u003Cem\u003ECA1\u003C\/em\u003E, or \u003Cem\u003ESMPD1\u003C\/em\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EAmlodipine is associated with lower self-reported ADHD symptoms in the UK Biobank, independent of hypertension\u003C\/h3\u003E\u003Cp id=\u0022p-29\u0022\u003EWe finally examined the effects of amlodipine in treating ADHD symptoms using the UK Biobank. ADHD is not among the health outcomes recorded in the initial UK Biobank assessment interview, although 42 individuals reported medications consistent with an ADHD diagnosis. Inpatient records identify an additional 11 individuals with the relevant ICD10 diagnosis code (F90). Given these small numbers, ADHD PRS cannot be validated directly against an ADHD diagnosis. Instead, we replicated a number of associations with ADHD risk comorbidities identified by Haan et al\u2019s\u003Csup\u003E\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E Estonian Biobank PheWAS for ADHD risk. Here, logistic regression identifies our ADHD PRS as a significant predictor of hypertension, chronic obstructive pulmonary disease, type 2 diabetes, obesity, mental and behavioral disorders due to use of alcohol, depressive episode, recurrent depressive disorder, and other anxiety disorders (Supplementary Figure 3). Among the UK Biobank assessment questions, we identified one related to mood swings and another related to risk-taking as most closely aligned with the ADHD phenotype itself, independent of the comorbidities previously identified. We find that amlodipine status is a significant predictor of both outcomes in logistic regression models with ADHD risk as a covariate \u2013 in particular, when ADHD risk is taken into account, individuals taking amlodipine are significantly less likely to report mood swings or a propensity for risk taking (\u003Ca id=\u0022xref-fig-5-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F5\u0022\u003EFigure 5\u003C\/a\u003E). In contrast, the antihypertensive Ramipril, an ACE inhibitor, shows no such effects (Supplementary Figure 4), highlighting the efficacy of amlodipine in mitigating symptoms of ADHD, not explained by its antihypertensive effects.\u003C\/p\u003E\u003Cdiv id=\u0022F5\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F5.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022UK Biobank mental health questionnaire responses as functions of ADHD risk score and amlodipine prescription status. Each row represents a logistic regression model where UK Biobank participants\u0026#x2019; responses to the question in the left-hand column are modeled as functions of ADHD risk score and amlodipine prescription status. The points plotted in the center and right-hand columns are the coefficient estimates for these two predictors with their corresponding p-values printed below. The bars around these points represent 95% confidence intervals for these estimates. Points and confidence interval bars in green indicate that the given predictor is significant (p \u0026lt; 0.05) in the given model.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-2049270684\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;\u0026lt;div xmlns=\u0026quot;http:\/\/www.w3.org\/1999\/xhtml\u0026quot;\u0026gt;\u0026lt;span class=\u0026quot;caption-title\u0026quot;\u0026gt;UK Biobank mental health questionnaire responses as functions of ADHD risk score and amlodipine prescription status.\u0026lt;\/span\u0026gt; Each row represents a logistic regression model where UK Biobank participants\u0026#x2019; responses to the question in the left-hand column are modeled as functions of ADHD risk score and amlodipine prescription status. The points plotted in the center and right-hand columns are the coefficient estimates for these two predictors with their corresponding p-values printed below. The bars around these points represent 95% confidence intervals for these estimates. Points and confidence interval bars in green indicate that the given predictor is significant (\u0026lt;em\u0026gt;p\u0026lt;\/em\u0026gt; \u0026lt; 0.05) in the given model.\u0026lt;\/div\u0026gt;\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 5.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022160\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 5.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F5.medium.gif\u0022 width=\u0022440\u0022 height=\u0022160\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F5.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 5.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/F5.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 5.\u003C\/span\u003E \u003Cspan class=\u0022caption-title\u0022\u003EUK Biobank mental health questionnaire responses as functions of ADHD risk score and amlodipine prescription status.\u003C\/span\u003E\u003Cp id=\u0022p-30\u0022 class=\u0022first-child\u0022\u003EEach row represents a logistic regression model where UK Biobank participants\u2019 responses to the question in the left-hand column are modeled as functions of ADHD risk score and amlodipine prescription status. The points plotted in the center and right-hand columns are the coefficient estimates for these two predictors with their corresponding p-values printed below. The bars around these points represent 95% confidence intervals for these estimates. Points and confidence interval bars in green indicate that the given predictor is significant (\u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 0.05) in the given model.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-10\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EDiscussion\u003C\/h2\u003E\u003Cp id=\u0022p-31\u0022\u003EIn the current experiments, we used zebrafish and rodent assays to assess the pre-clinical efficacy of five previously identified novel putative ADHD therapeutics and MR to gauge human genetic support. We show that of the five candidates identified in a prior screen (aceclofenac, amlodipine, doxazosin, moxonidine and LNP599), only amlodipine demonstrated efficacy in the rodent assay. Therefore, we focused the subsequent experiments on amlodipine and, notably, used MR to demonstrate a causal correlation of variants in amlodipine target genes on ADHD in a human genetic sample.\u003C\/p\u003E\u003Cp id=\u0022p-32\u0022\u003EThe SHR model is widely regarded as the gold standard for studying ADHD in mammals.\u003Csup\u003E\u003Ca id=\u0022xref-ref-8-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E Therefore, we first conducted a re-assessment of the potentially therapeutic compounds previously identified using the OFT in SHR vs the WKY controls. Amlodipine did not affect rearing frequency, indicative of anxiety, but reduced two measures of hyperactivity: distance traveled and ambulatory time. Other compounds tested did not. The assay was done using a single dose so it cannot be ruled out that other compounds are efficacious using a different dose. Importantly, the fact that amlodipine was efficacious argues strongly for translatability since the assay differed greatly from the initial larval zebrafish screen: it was performed in a mammal with a different genetic background\u003Csup\u003E\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E\u003C\/sup\u003E and using long-term i.p. injections, as opposed to the acute immersion administration in the zebrafish. The study thus extends the reduction of a hyperactive phenotype to a mammalian system with a different genetic background.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003E5-CSRTT is a behavioral assay adapted from rodents and developed to assess various aspects of attention, impulsivity, and cognitive function.\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E It is designed to measure an animal\u2019s ability to sustain attention, make accurate and timely responses, and inhibit impulsive responses. In the assay, impulsivity is operationalized specifically as responses occurring prior to the stimulus onset (i.e., premature or anticipatory responding). In the current experiment, this assay is used to extend the measurement of the efficacy of amlodipine from hyperactivity to impulsivity in adult zebrafish \u003Cem\u003Eadgrl3.1\u003C\/em\u003E mutants. We show that amlodipine effectively rescues impulsivity in the 5-CSRTT and the effect compares to that of methylphenidate (Cohen\u2019s d = 0.62 and 0.59, respectively).\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003EThe efficacy of amlodipine in rescuing key features of ADHD in both rodent and zebrafish models raised the question of similar effects of other LTCCBs. We thus assayed 12 additional antihypertensive LTCCBs in the larval hyperactive screening assay.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E Seven of the 12 LTCCBs induced significant reduction in the hyperactivity larval zebrafish model. Neurotoxicity was common at higher doses and effects were more variable than those of amlodipine. We can conclude, first, the effects of amlodipine cannot be explained by general antihypertensive properties of LTTCBs and, second, that the effects are dependent on specific L-type calcium channel target engagement.\u003C\/p\u003E\u003Cp id=\u0022p-35\u0022\u003EAmlodipine is widely reported to have a low brain penetration.\u003Csup\u003E\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E\u003C\/sup\u003E Rodent data indicate approximately 20-fold lower brain penetration than nifedipine and nimodipine.\u003Csup\u003E\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E\u003C\/sup\u003E The current data is hard to understand in the absence of BBB penetration. Indeed, other authors have concluded that amlodipine crosses the BBB to account for their data.\u003Csup\u003E\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E\u003C\/sup\u003E Amlodipine exhibits a very slow dissociation from binding sites, suggesting that strong central effects could be achieved by brain accumulation.\u003Csup\u003E\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E\u003C\/sup\u003E In the current experiment, we show that amlodipine reduces central c-Fos expression and crosses the BBB at therapeutic dose in adult \u003Cem\u003Eadgrl3.1\u003C\/em\u003E\u003Csup\u003E-\/-\u003C\/sup\u003E zebrafish. We conclude that the effects reported here are driven by the engagement of amlodipine with central L-type calcium channels.\u003C\/p\u003E\u003Cp id=\u0022p-36\u0022\u003EMR is a robust and accessible tool for examining the causal relationship between an exposure and an outcome from GWAS summary statistics using genetic variants.\u003Csup\u003E\u003Ca id=\u0022xref-ref-12-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/sup\u003E MR leverages randomly allocated genetic variants as instrumental variables for studying the effect of varying exposure. The random allocation of genetic variants at conception means that this paradigm is less vulnerable to environmental confounding and reverse causation bias that can hinder causal inference in traditional epidemiological study designs. Naturally occurring variations in genes coding for drug target proteins can be leveraged to inform on the effect of their pharmacological perturbation.\u003Csup\u003E\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E\u003C\/sup\u003E Association between a relevant genetic variant affecting the exposure and the outcome may be taken as evidence for the potential efficacy of a drug affecting the exposure pathway.\u003Csup\u003E\u003Ca id=\u0022xref-ref-12-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-37\u0022\u003EWe report a new approach for drug-target MR to account for polypharmacology and utilize it to examine the differential effects of amlodipine on hypertension and ADHD. We could reproduce the well-established effect of amlodipine on hypertension. Significant effects were caused by the variance in the genes encoding for the \u03b1\u003Csub\u003E1\u003C\/sub\u003E subunits of all three calcium channel subtypes investigated as well as by all amlodipine target genes combined. This aligns with the fact that the \u03b1\u003Csub\u003E1\u003C\/sub\u003E subunit forms the Ca\u003Csup\u003E2+\u003C\/sup\u003E selective pore, housing both voltage-sensing machinery and the drug\/toxin-binding sites. Differences in significant mediating traits suggest varying biochemical pathways. Importantly, we also found significant causal effects on ADHD, supporting our animal studies. Interestingly, these were caused only by the variance in the genes encoding for three tested subunits of L-type calcium channels and by all amlodipine target genes combined. These results suggest a major role of voltage-gated L-type calcium channels in the effect of amlodipine on ADHD.\u003C\/p\u003E\u003Cp id=\u0022p-38\u0022\u003EThe very low rates of ADHD diagnosis in the UK Biobank precluded the assessment of amlodipine prescription on the disorder in that cohort directly, so we constructed a PRS to estimate the genetic liability of ADHD outside of diagnosis.\u003Csup\u003E\u003Ca id=\u0022xref-ref-14-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E We cross-checked ADHD risk and associated medical conditions with amlodipine prescriptions. As reported previously, ADHD genetic liability is strongly associated with numerous medical conditions\u003Csup\u003E\u003Ca id=\u0022xref-ref-14-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E which are positively impacted by amlodipine prescriptions. Here, we found that self-reported mood swings and risk taking were reversed by amlodipine, clearly demonstrating the effect in a human population.\u003C\/p\u003E\u003Cp id=\u0022p-39\u0022\u003EAmlodipine possesses several strengths for repurposing, including a well-established safety profile, low risk of drug interactions, FDA approval, affordability as a generic medication, and a known mechanism of action. Amlodipine has been reported to bind seven proteins, including subunit \u03b1\u003Csub\u003E1\u003C\/sub\u003E-C of the voltage-dependent calcium channels of type L, the coding gene of which is consistently implicated in neuropsychiatric disorders, including ADHD.\u003Csup\u003E\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E\u003C\/sup\u003E LTCCs play roles in neuronal firing patterns, activity-dependent transcription regulation through calcium second messenger pathways, and the release of monoamines, affecting the prefrontal cortex\u003Csup\u003E\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\u003C\/sup\u003E and are, therefore, poised to modulate neural circuits important for ADHD. Amlodipine could, therefore, directly affect symptoms of ADHD via neurotransmitter release and neuronal excitability. In particular, calcium ions play a role in releasing neurotransmitters like dopamine and norepinephrine. These neurotransmitters are known to be involved in the regulation of attention, focus, and impulse control, all of which are affected in ADHD. Moreover, amlodipine is neuroprotective, beyond its blood pressure lowering effect, by modulating neuroinflammation, protecting mitochondrial structure and function and reducing oxidative stress\u003Csup\u003E\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E\u003C\/sup\u003E and may thus affect a neural root cause of ADHD.\u003Csup\u003E\u003Ca id=\u0022xref-ref-27-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-27\u0022\u003E27\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-28-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-28\u0022\u003E28\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-40\u0022\u003EIn conclusion, we show that amlodipine is effective in reducing hyperactivity and impulsivity in zebrafish and rodent models of ADHD; we implemented a new approach to study polypharmacology using drug-target MR, and validated the effect of amlodipine on ADHD in human genetic data, demonstrating mitigating effects in a human population. To the best of our knowledge, this is the first drug-target MR study using instrumental variables from multiple drug target genes. We conclude that amlodipine holds a strong potential to be developed as a novel therapeutic to treat ADHD in humans.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-11\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EMethods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ESHR rat Open Field Test Housing and rodent care\u003C\/h3\u003E\u003Cp id=\u0022p-41\u0022\u003EWKY wild-type (n = 20) and SHR (n = 140) strains were purchased from The Center for Research Libraries, Germany. Animals ranged from 5 to 7 weeks old upon arrival and were housed in open-topped polycarbonate cages with a 13:11-h light-dark cycle under a constant temperature of 20-23 \u00b0C and relative humidity of 40-70%. All animals were provided standard chow (Teklad Global 2016) and water, each accessible ad libitum. The subjects underwent a two-week acclimation and handling period before the experimental procedures. Each subject was marked with a unique identification number using tail marks with permanent marker according to the Standard Operating Procedures of the Testing Facility. All animal experiments were performed as specified in the license authorized by the National Animal Experiment Board of Finland (ESAVI\/20200\/2021) and according to the National Institutes of Health (Bethesda, MD, USA) guidelines for the care and use of laboratory animals.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDrug treatment\u003C\/h3\u003E\u003Cp id=\u0022p-42\u0022\u003EAfter the initial two-week acclimation and handling period, the SHR rats were divided into seven groups (n = 20 per group). For 30 days, these groups were administered a control vehicle (90% Acetate buffer, 10% Propylene Glycol), clonidine (0.01 mg\/kg) (MedChem Express, Monmouth Junction, USA), moxonidine (0.5 mg\/kg), doxazosin (8 mg\/kg), amlodipine (10 mg\/kg), aceclofenac (5 mg\/kg) (all from Cayman Chemicals, Michigan, USA) or LNP599 (10 mg\/kg) (Green Pharma, Orl\u00e9ans, France). A group of WKY rats (n = 20) dosed with a vehicle served as an additional control group. The administration of treatments was performed via intraperitoneal injections, delivered daily at a volume of 10 ml\/kg throughout the 30 study days. Each group maintained a balanced sex distribution, with ten females and ten males.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EOpen Field Tests\u003C\/h3\u003E\u003Cp id=\u0022p-43\u0022\u003EOFT was conducted twice for all rats: one day before initiating the dosing regimen (D0) and the 29th study day (D29). Testing occurred during the light phase between 14:00-16:00, roughly 6 hours post-dosing. Prior to the assessment, rats were given a 1-hour acclimation period in the test room. The test utilized activity chambers (Med Associates Inc, St Albans, VT; dimensions: 27 x 27 x 20.3 cm) fitted with infrared beams. Rats were individually positioned at the center of the chamber, and behavioral observations were recorded in 5-minute intervals over a 30-minute duration. Quantitative analysis was performed on the following five dependent measures: total locomotion, locomotion in the center of the open field, rearing rate in the center, total rearing frequency, and velocity. Testing conditions were optimized to minimize stress, with ambient light intensity set between 10 and 30 lux using red light. Within the enclosed chamber, light intensity ranged from 0 to 5 Lux.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-15\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical analysis\u003C\/h3\u003E\u003Cp id=\u0022p-44\u0022\u003EGroup comparisons for distance traveled, rearing frequency, and velocity for all eight groups were analyzed using a mixed-model approach (REML), followed by a post-hoc analysis with Fisher\u2019s LSD test without correction. Evaluations of differences in ambulatory episodes and central zone entries were performed using the same mixed-model framework (REML), followed by post-hoc analysis with Tukey\u2019s multiple comparisons test. When evaluating the effect of amlodipine on the SHR rats in comparison to the vehicle-treated SHR and WKY rats, for distance traveled, rearing frequency, ambulatory time, and central zone entries, analyses were performed using a mixed-model approach (REML), followed by post-hoc analysis with Tukey\u2019s multiple comparisons test.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Ezebrafish 5-CSRTT\u003C\/h3\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EHousing and generation of fish line\u003C\/h4\u003E\u003Cp id=\u0022p-45\u0022\u003EHomozygous \u003Cem\u003Eadgrl3.1\u003C\/em\u003E knock-out zebrafish (\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E) created through CRISPR-Cas9 (described previously\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E), alongside age-matched \u003Cem\u003Eadgrl3.1\u003Csup\u003E+\/+\u003C\/sup\u003E\u003C\/em\u003E control fish were used. The fish were housed in a University of Portsmouth (UK) aquarium facility, maintained on a 14:10 light:dark cycle at 28\u00b0C (pH \u223c 8). The \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Eand control fish were bred concurrently through pair breeding and raised until they reached four months post-fertilization. All tanks were equipped with enrichment substrates, starting from 10 days post-fertilization (dpf). Offspring from both groups were randomly selected for experiments, maintaining equal sex distribution. All work was carried out following ethical approval from the University of Portsmouth Animal Welfare and Ethical Review Body (AWERB) and under license from the UK Home Office (PPL P9D87106F).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EDrug treatment\u003C\/h3\u003E\u003Cp id=\u0022p-46\u0022\u003EThe \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E fish received individual immersion in 10D\u00b5M amlodipine (Cambridge bioscience Ltd, Chambridge, UK) for a 30-minute duration before behavioral recording. The dose was based on the established effective dose from Sveinsd\u00f3ttir et al.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E. To administer the drug, it was dissolved in aquarium-treated water, and each fish was individually treated in 300DmL beakers. In the case of the 5-CSRTT, amlodipine treatment occurred after achieving steady-state responses in the final phase of the task.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E5-CSRTT\u003C\/h3\u003E\u003Cp id=\u0022p-47\u0022\u003EAdult \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E show high levels of impulsivity in the 5-CSRTT, which is rescued with atomoxetine.\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E Here, we trained adult \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003Ezebrafish (nD=D48; power analyses based on previous work from our group showing medium-large effect sizes on the 5-CSRTT (\u003Ca id=\u0022xref-fig-2-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2 A\u003C\/a\u003E),\u003Csup\u003E\u003Ca id=\u0022xref-ref-10-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E a validated test for measuring impulsivity in zebrafish.\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E The task involves training the fish to respond to a light stimulus in one of five locations in a specialized testing arena (Zantiks AD, Cambridge, UK). Training on the 5-CSRTT has been reported extensively elsewhere.\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EBriefly, initiation training comprised 4 distinct stages, each lasting \u223c1-2 weeks (depending on fish performance). Fish were trained once\/day in sessions that lasted 30 trials (typically \u223c30-45 min). Following habituation to the test tank, in Stage 1, fish were trained that swimming over any of the lights in the tank is reinforced with a small food reward (\u223c2mg ZM-400 dry feed [ZM systems, Winchester, UK] delivered via an automated feeder upon correct responses). In Stage 2, fish were trained to initiate a trial by swimming over the initiator light. Again, in this stage, correct responses were reinforced with a food reward. In Stage 3, in order to be reinforced fish were required to activate one of the 5 stimulus lights, all of which are illuminated simultaneously following a correct initiator light activation. In the final pre-training stage, Stage 4, fish were required to locate and activate a single stimulus light following a correct initiator light activation. Finally, fish were trained on the 5-CSRTT over 2 phases (each lasting \u223c5 days). In Phase 1, trials are initiated by activation of the initiator light, and then, following a variable-interval 5-sec inter-trial interval (ITI), one of the 5 stimulus lights is illuminated. Fish were required to swim into the correct stimulus light aperture in order to be reinforced. Commission errors, including incorrect responses (ie swimming into the incorrect aperture) or premature responses (ie swimming into any aperture prior to illumination of a stimulus light), or omission errors (ie failing to swim into an aperture during illumination of the stimulus light) resulted in no reinforcement, and a 10-sec \u2018time out\u2019. In the second stage of 5-CSRTT training, the task is identical, except the ITI is increased to VI-10-sec.\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003EImpulsivity is assessed in the second stage of the 5-CSRTT by quantifying fish\u2019s ability to withhold the response to the light stimulus during a defined pre-stimulus interval (usually a variable 5-second interval).\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EDrug treatment was carried out in a pseudo-counterbalanced order (amlodipine, methylphenidate), with a maximum of one drug exposure per week. For example, baseline recording was carried out on Monday and Tuesday, drug treatment Wednesday, followed by baseline Thursday and Friday. Drug exposures were replicated to ensure reliability. During drug treatment, fish were exposed for 30-min immediately prior to 5-CSRTT testing in a 1L tank (fish were isolated during drug treatment). They were then removed from the drug, and placed immediately into the 5-CSRTT apparatus, and training commenced.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-20\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EStatistical analysis\u003C\/h3\u003E\u003Cp id=\u0022p-51\u0022\u003EData from the 5-CSRTT were analyzed in two separate analyses. First, differences between baseline responses of WT and \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E fish were analyzed using a \u003Cem\u003Et\u003C\/em\u003E-test. Second, data pertaining to drug responses (amlodipine, methylphenidate) in \u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E fish were analyzed using linear mixed effects models (fixed factors were drug [baseline vs. amlodipine 10 \u00b5M vs. methylphenidate 10 \u00b5M], outcomes were proportion correct responses and proportion premature responses, random effects was fish ID). Data are presented as mean \u00b1 SEM. A \u003Cem\u003Ep\u003C\/em\u003E-value threshold of less than 0.05 was set for statistical significance. All statistical analysis and graphs were generated using GraphPad software (GraphPad Software, CA, USA).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-21\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003ELarval assay\u003C\/h3\u003E\u003Cp id=\u0022p-52\u0022\u003E\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E and WT zebrafish larvae were assayed and analyzed for hyperactivity and sleep parameters as previously described.\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E Twelve different LTCCBs were evaluated: cilnidipine, diltiazem, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, and verapamil (Greenpharma, Orl\u00e9ans, France). All drugs were assessed at three different concentrations, 1 \u00b5M, 10 \u00b5M, and 30 \u00b5M, except for felodipine which was assessed at 0.1 \u00b5M, 1 \u00b5M, and 5 \u00b5M (n = 24 for each group) and compared to larvae treated with 0.3% DMSO. Each drug was recorded twice, and statistical analysis performed on the pooled data. All procedures in this study were carried out in strict compliance with the regulations of and approved by the National Bioethics Committee of Iceland (regulation 460\/2017).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-22\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EBlood-brain barrier penetration\u003C\/h3\u003E\u003Cp id=\u0022p-53\u0022\u003E\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E zebrafish (n = 12) were exposed to 10 \u00b5M of amlodipine or vehicle for a duration of 30 minutes (as above). Following the exposure, they were transferred to system water for rinsing before euthanization and brain extraction. Waters UPLC I-Class Plus (Waters Corporation, CT, USA) tandom Q Exactive high-resolution mass spectrometer (Thermo Fisher Scientific, MA, USA) was used to analyze the brain samples for quantification of amlodipine. Four ion transitions, 238.6 m\/z, 294.2 m\/z, 377.2 m\/z, and 392.1 m\/z, were considered, and the quantitative verification of amlodipine required at least two ion transitions for confirmation.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-23\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EC-Fos imaging\u003C\/h3\u003E\u003Cp id=\u0022p-54\u0022\u003E\u003Cem\u003Eadgrl3.1\u003Csup\u003E-\/-\u003C\/sup\u003E\u003C\/em\u003E and WT zebrafish larvae (5 dpf) were exposed to 10 \u00b5M of amlodipine or 0.1% DMSO for 24 hours in a 96-well plate (n = 20 per group). Immediately following exposure, immunohistochemical staining was conducted, as detailed in Sveinsd\u00f3ttir et al.\u003Csup\u003E\u003Ca id=\u0022xref-ref-29-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-29\u0022\u003E29\u003C\/a\u003E\u003C\/sup\u003E Fluorescent images were acquired using an Olympus IX33 confocal microscope (Olympus, Tokyo, Japan). For c-Fos quantification, the brain was imaged using a 30X magnification objective. Image stacks were individually analyzed, and c-Fos in the telencephalon was quantified using ImageJ Fiji software.\u003Csup\u003E\u003Ca id=\u0022xref-ref-30-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-30\u0022\u003E30\u003C\/a\u003E\u003C\/sup\u003E A predefined area within the telencephalon was selected and consistently utilized for the analysis across all images. This procedure was conducted twice, and the statistical analysis was performed on the pooled data using GraphPad Prism 10.2.1 software (GraphPad Software, CA, USA).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-24\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EMendelian randomization\u003C\/h3\u003E\u003Cdiv id=\u0022sec-25\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EDatasets\u003C\/h4\u003E\u003Cp id=\u0022p-55\u0022\u003EWe used hypertension summary statistics with 1,237 cases and 359,957 controls provided by FinnGen\u003Csup\u003E\u003Ca id=\u0022xref-ref-31-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-31\u0022\u003E31\u003C\/a\u003E\u003C\/sup\u003E and a recent meta-analysis comprising 38,691 individuals with ADHD and 186,843 controls\u003Csup\u003E\u003Ca id=\u0022xref-ref-32-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-32\u0022\u003E32\u003C\/a\u003E\u003C\/sup\u003E as outcomes.\u003C\/p\u003E\u003Cp id=\u0022p-56\u0022\u003EThe manually curated list of traits includes blood cell counts, metabolites, amino acids, lipids, and enzymes. A total of 140 GWAS summary statistics were used as exposures for the MR experiments, covering measurements of the body, enzymes, blood cells and their proteins, lipids, fatty acids, as well as small molecules, such as amino acids, ketones, and glycolysis metabolites (Supplementary Table 1). All exposure datasets, with the exception of estimated glomerular filtration rate (eGFR) summary statistics, were generated using samples from individuals of European ancestry in the UK Biobank.\u003Csup\u003E\u003Ca id=\u0022xref-ref-33-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-33\u0022\u003E33\u003C\/a\u003E\u003C\/sup\u003E Of the 140 exposure datasets, 78 were produced by Nightingale Health in their disease-wide association scan of plasma nuclear magnetic resonance (NMR) biomarkers for 118,444 individuals.\u003Csup\u003E\u003Ca id=\u0022xref-ref-34-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-34\u0022\u003E34\u003C\/a\u003E\u003C\/sup\u003E An additional 45 datasets were produced by The Neale Lab (\u003Ca href=\u0022http:\/\/www.nealelab.is\/uk-biobank\/\u0022\u003Ehttp:\/\/www.nealelab.is\/uk-biobank\/\u003C\/a\u003E) following their GWAS analysis (version 3) of over 7,000 phenotypes using samples from 361,194 individuals. For three traits - neutrophil count over lymphocyte count, platelet count over lymphocyte count, and aspartate aminotransferase over alanine aminotransferase - GWAS were run in-house based on UK Biobank data. The dataset for estimated Glomerular Filtration Rate (eGFR) was produced by Wuttke \u003Cem\u003Eet al.\u003C\/em\u003E\u003Csup\u003E\u003Ca id=\u0022xref-ref-35-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-35\u0022\u003E35\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-26\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EData pre-processing\u003C\/h4\u003E\u003Cp id=\u0022p-57\u0022\u003EThe datasets were pre-processed with version 1.7.8 of the tool MungeSumstats,\u003Csup\u003E\u003Ca id=\u0022xref-ref-36-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-36\u0022\u003E36\u003C\/a\u003E\u003C\/sup\u003E using default parameters. These include checking to ensure variants are on the respective human reference (GRCh38\/Hg18 or GRCh37\/Hg19 depending on the datasets), removing duplicate SNPs, and removing multi-allelic SNPs (according to the SNP database db144).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-27\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EMendelian randomization\u003C\/h4\u003E\u003Cp id=\u0022p-58\u0022\u003EFirst, pre-processed summary statistics files were read and thresholds were applied to the exposure SNPs to ensure they were valid instruments. The \u003Cem\u003Ep\u003C\/em\u003E-value threshold was \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 5E\u221208 for genome-wide experiments and \u003Cem\u003Ep\u003C\/em\u003E \u0026lt; 1E\u221204 for drug-target experiments. Independent SNPs were identified by performing linkage disequilibrium (LD) clumping to discard SNPs in LD with another variant with a smaller \u003Cem\u003Ep\u003C\/em\u003E-value association based on the European reference panel from the 1000 Genomes Project (\u003Ca href=\u0022https:\/\/www.internationalgenome.org\/home\u0022\u003Ehttps:\/\/www.internationalgenome.org\/home\u003C\/a\u003E) using the ld_clump() function of the R package ieugwasr (\u003Ca href=\u0022https:\/\/github.com\/MRCIEU\/ieugwasr\u0022\u003Ehttps:\/\/github.com\/MRCIEU\/ieugwasr\u003C\/a\u003E), which provides a wrapper around PLINK.\u003Csup\u003E\u003Ca id=\u0022xref-ref-37-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-37\u0022\u003E37\u003C\/a\u003E\u003C\/sup\u003E Variants were only included that are correlated at r\u003Csup\u003E2\u003C\/sup\u003E \u0026lt; 0.001 for genome-wide, or r\u003Csup\u003E2\u003C\/sup\u003E \u0026lt; 0.1 for drug-target MR experiments. The window was set to 10Mbp in both cases, which is the default used by the ld_clump() function. If at least three SNPs remained as instrumental variables, the MR-R\u00fccker framework\u003Csup\u003E\u003Ca id=\u0022xref-ref-38-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-38\u0022\u003E38\u003C\/a\u003E\u003C\/sup\u003E was utilized to decide whether IVW or MR-Egger is best supported by the data. Otherwise, the Inverse-variance weighted (IVW method) for two SNPs or the Wald ratio method (one SNP) were used.\u003Csup\u003E\u003Ca id=\u0022xref-ref-39-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-39\u0022\u003E39\u003C\/a\u003E\u003C\/sup\u003E All methods were implemented in the TwoSampleMR package.\u003Csup\u003E\u003Ca id=\u0022xref-ref-40-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-40\u0022\u003E40\u003C\/a\u003E\u003C\/sup\u003E\u003C\/p\u003E\u003Cp id=\u0022p-59\u0022\u003EIn order to take the multiple drug targets of amlodipine into consideration, we extended the common practice in drug-target MR to draw variants from genes that are associated with an exposure by providing multiple gene ranges from which variants could be selected. We provided flanks of 5 kbp around each gene large enough to try and capture as many relevant variants, but with as little overlap with neighboring genes as is feasible.\u003C\/p\u003E\u003Cp id=\u0022p-60\u0022\u003EEffect estimates correspond to the log odds of the outcome per copy of the effect allele.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-28\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003EPolygenic Risk Score Analysis\u003C\/h3\u003E\u003Cp id=\u0022p-61\u0022\u003EThe UK Biobank is a prospective study of over 500,000 UK residents recruited from 2006 to 2010. Upon initial assessment, participants responded to socio-demographic, lifestyle, and health-related questions via a touch-screen questionnaire and an interview before completing a range of physical measures and providing blood, urine, and saliva samples, which were the basis for biomarker assays and for genotyping and imputation. Longitudinal data consists primarily of linkages with national datasets including hospital inpatient health records.\u003C\/p\u003E\u003Cp id=\u0022p-62\u0022\u003EStarting from summary statistics for an ADHD GWAS of a European population\u003Csup\u003E\u003Ca id=\u0022xref-ref-41-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-41\u0022\u003E41\u003C\/a\u003E\u003C\/sup\u003E and filtering for genetic variants available in the UK Biobank imputation data, we applied the PRS-CS-auto algorithm to infer posterior effect estimates for these variants using an external linkage disequilibrium reference panel for a European population.\u003Csup\u003E\u003Ca id=\u0022xref-ref-42-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-42\u0022\u003E42\u003C\/a\u003E\u003C\/sup\u003E These estimates, along with the individual-level UK Biobank imputation data, were the basis for the computation of individual-level, per-chromosome ADHD polygenic risk scores for UK Biobank participants using PLINK 2.0\u003Csup\u003E\u003Ca id=\u0022xref-ref-43-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-43\u0022\u003E43\u003C\/a\u003E\u003C\/sup\u003E. Individual-level genome-wide risk scores were then computed as the weighted mean of per-chromosome scores, with weights calculated at the individual-level to account for within-chromosome missing variant data. That is, \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2024\/05\/31\/2024.05.30.24308216\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E, where \u003Cem\u003EPRS\u003Csub\u003Eji\u003C\/sub\u003E\u003C\/em\u003E and \u003Cem\u003EK\u003Csub\u003Eji\u003C\/sub\u003E\u003C\/em\u003E represent, respectively, for an individual \u003Cem\u003Ej\u003C\/em\u003E, the mean posterior effect estimate for chromosome \u003Cem\u003Ei\u003C\/em\u003E and the number of variants present in \u003Cem\u003Ei\u003C\/em\u003E. Risk scores were subsequently standardized for convenience.\u003C\/p\u003E\u003Cp id=\u0022p-63\u0022\u003EPrior to analysis, the UK Biobank cohort was subject to quality control filters to exclude individuals missing data for sex (as determined from genotyping analysis) or assessment age, cases of sex chromosome aneuploidy, outliers for heterozygosity or missing rate, and individuals of non-European ethnic background. We identified case status for medications and health outcomes of interest on the basis of self-reports at assessment. Alternative indicators for health outcomes were identified on the basis of ICD10 codes registered in the longitudinal hospital inpatient data. Finally, case status for mood swings and risk-taking were identified on the basis of responses, respectively, to touchscreen questions \u201cDoes your mood often go up and down?\u201d and \u201cWould you describe yourself as someone who takes risks?\u201d\u003C\/p\u003E\u003Cp id=\u0022p-64\u0022\u003ETo assess associations of ADHD risk scores with health outcomes of interest, we trained multiple logistic regression models on our UK Biobank cohort with ADHD risk score as an independent predictor. To assess the effects of amlodipine on mood swings and risk-taking behavior, we trained a logistic regression model for each outcome with ADHD risk score and amlodipine status as independent predictors.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-30\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-65\u0022\u003EThe data that support the findings of this study are available from the corresponding author upon reasonable request.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-31\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAuthor contribution\u003C\/h2\u003E\u003Cp id=\u0022p-67\u0022\u003ED.\u00de.H., H.S.S. ran larval assays; M.P., D.\u00de.H. ran blood-brain barrier penetration assay; B.G. ran c-Fos study; C.H., J.R.-T. ran 5-CSRTT assay; D.\u00de.H., H.S.S., B.G., and H.\u00de. analyzed data; H.A.B., M.F.S. ran MR analysis; J.L.C., M.F.S. ran PRS analysis. K.\u00c6.K. conceived experiments. M.P., H.\u00de., M.F.S., H.A.B. and K.\u00c6.K. designed experiments. All authors edited the manuscript; K.\u00c6.K. wrote the manuscript.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-32\u0022\u003E\u003Ch2 class=\u0022\u0022\u003ECompeting interests\u003C\/h2\u003E\u003Cp id=\u0022p-68\u0022\u003EK.\u00c6.K., H.\u00de., H.S.S., D.\u00de.H., and B.G. are employees of 3Z Pharma. H.A.B., J.L.C., and M.F.S are employees of biotx.ai GmbH.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ack\u0022 id=\u0022ack-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAcknowledgement\u003C\/h2\u003E\u003Cp id=\u0022p-66\u0022\u003E3Z is supported by Icelandic Technology Development Fund grant no. 2220781-601. The research work at biotx.ai GmbH was supported by the Investitionsbank des Landes Brandenburg (ILB), the European Regional Development Fund (ERDF), and the European Social Fund+ (ESF+). The research has been conducted using the UK Biobank Resource under Application no. 36226.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENigg\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. T.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESibley\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. H.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThapar\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKaralunas\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. L\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EDevelopment of ADHD: Etiology\u003C\/span\u003E, \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHeterogeneity, and Early Life Course. Annu Rev Dev Psychol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E2\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E559\u003C\/span\u003E\u2013 \u003Cspan class=\u0022cit-lpage\u0022\u003E583\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHeterogeneity%252C%2Band%2BEarly%2BLife%2BCourse.%2BAnnu%2BRev%2BDev%2BPsychol%26rft.volume%253D2%26rft.spage%253D559%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESibley\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. H.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EVariable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm. J. Psychiatry\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E179\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E142\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E151\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm.%2BJ.%2BPsychiatry%26rft.volume%253D179%26rft.spage%253D142%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.3\u0022 data-doi=\u002210.1177\/2045125317734977\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGeffen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EForster\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ETreatment of adult ADHD: a clinical perspective\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETher Adv Psychopharmacol\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E8\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E25\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E32\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTher%2BAdv%2BPsychopharmacol%26rft.volume%253D8%26rft.spage%253D25%26rft_id%253Dinfo%253Adoi%252F10.1177%252F2045125317734977%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1177\/2045125317734977\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.4\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBriars\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETodd\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EA Review of Pharmacological Management of Attention-Deficit\/Hyperactivity Disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ. Pediatr. Pharmacol. Ther\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E21\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E192\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E206\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2016\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ.%2BPediatr.%2BPharmacol.%2BTher%26rft.volume%253D21%26rft.spage%253D192%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.5\u0022 data-doi=\u002210.1056\/NEJMra1917069\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECortese\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPharmacologic Treatment of Attention Deficit-Hyperactivity Disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN. Engl. J. Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E383\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1050\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1056\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN.%2BEngl.%2BJ.%2BMed%26rft.volume%253D383%26rft.spage%253D1050%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMra1917069%26rft_id%253Dinfo%253Apmid%252Fhttp%253A%252F%252Fwww.n%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMra1917069\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=http:\/\/www.n\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMamiya\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. C.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EArnett\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. B.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStein\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. A\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPrecision Medicine Care in ADHD: The Case for Neural Excitation and Inhibition\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBrain Sci\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E11\u003C\/span\u003E, (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.7\u0022 data-doi=\u002210.1038\/s41386-022-01505-z\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESveinsd\u00f3ttir\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH. S.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ENovel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENeuropsychopharmacology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E48\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1155\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1163\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNeuropsychopharmacology%26rft.volume%253D48%26rft.spage%253D1155%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41386-022-01505-z%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41386-022-01505-z\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.8\u0022 data-doi=\u002210.1016\/J.NEUBIOREV.2021.11.041\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERegan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. L.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWilliams\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. T.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVorhees\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. V\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EReview of rodent models of attention deficit hyperactivity disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENeurosci. Biobehav. Rev\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E132\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E621\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E637\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNeurosci.%2BBiobehav.%2BRev%26rft.volume%253D132%26rft.spage%253D621%26rft_id%253Dinfo%253Adoi%252F10.1016%252FJ.NEUBIOREV.2021.11.041%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/J.NEUBIOREV.2021.11.041\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.9\u0022 data-doi=\u002210.1007\/s00213-014-3439-z\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EParker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. O.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrock\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. J.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESudwarts\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrennan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. H\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAtomoxetine reduces anticipatory responding in a 5-choice serial reaction time task for adult zebrafish\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPsychopharmacology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E231\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2671\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2679\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPsychopharmacology%26rft.volume%253D231%26rft.spage%253D2671%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs00213-014-3439-z%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1007\/s00213-014-3439-z\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFontana\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. D.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003Eadgrl3.1-deficient zebrafish show noradrenaline-mediated externalizing behaviors, and altered expression of externalizing disorder-candidate genes, suggesting functional targets for treatment\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ETransl. Psychiatry\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E304\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DTransl.%2BPsychiatry%26rft.volume%253D13%26rft.spage%253D304%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.11\u0022 data-doi=\u002210.1371\/journal.pgen.1008489\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKing\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. A.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDavis\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. W.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDegner\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. F\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EAre drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E15\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003Ee1008489\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2BGenet%26rft.volume%253D15%26rft.spage%253De1008489%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pgen.1008489%26rft_id%253Dinfo%253Apmid%252F31830040%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1371\/journal.pgen.1008489\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31830040\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.12\u0022 data-doi=\u002210.1016\/j.ajhg.2022.12.017\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurgess\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUsing genetic association data to guide drug discovery and development: Review of methods and applications\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm. J. Hum. Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E110\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E195\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E214\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm.%2BJ.%2BHum.%2BGenet%26rft.volume%253D110%26rft.spage%253D195%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.ajhg.2022.12.017%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.ajhg.2022.12.017\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.13\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EParker\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. O.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EDevelopment and automation of a test of impulse control in zebrafish\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EFront. Syst. Neurosci\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E65\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DFront.%2BSyst.%2BNeurosci%26rft.volume%253D7%26rft.spage%253D65%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.14\u0022 data-doi=\u002210.1101\/2022.11.28.22282824\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHaan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAssociations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: Utilizing electronic health records in a Phenome-Wide Association Study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EbioRxiv\u003C\/abbr\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E)\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1101\/2022.11.28.22282824\u003C\/span\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DbioRxiv%26rft_id%253Dinfo%253Adoi%252F10.1101%252F2022.11.28.22282824%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1101\/2022.11.28.22282824\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.15\u0022 data-doi=\u002210.33549\/physiolres.932622\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPravenec\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ERecent progress in the genetics of spontaneously hypertensive rats\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPhysiol. Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E63\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003ES1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E8\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPhysiol.%2BRes%26rft.volume%253D63%26rft.spage%253DS1%26rft_id%253Dinfo%253Adoi%252F10.33549%252Fphysiolres.932622%26rft_id%253Dinfo%253Apmid%252F24564651%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.33549\/physiolres.932622\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24564651\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.16\u0022 data-doi=\u002210.1038\/s41380-022-01615-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EColbourne\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHarrison\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EP. J\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBrain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EMol. Psychiatry\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E27\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E3904\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E3912\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DMol.%2BPsychiatry%26rft.volume%253D27%26rft.spage%253D3904%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41380-022-01615-6%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41380-022-01615-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.17\u0022 data-doi=\u002210.1016\/S0024-3205(97)00881-3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EUchida\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYamada\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENagai\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeguchi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKimura\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EBrain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELife Sci\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E61\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E2083\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2090\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E1997\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLife%2Bsciences%26rft.stitle%253DLife%2BSci%26rft.aulast%253DUchida%26rft.auinit1%253DS.%26rft.volume%253D61%26rft.issue%253D21%26rft.spage%253D2083%26rft.epage%253D2090%26rft.atitle%253DBrain%2Bpharmacokinetics%2Band%2Bin%2Bvivo%2Breceptor%2Bbinding%2Bof%2B1%252C4-dihydropyridine%2Bcalcium%2Bchannel%2Bantagonists.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0024-3205%252897%252900881-3%26rft_id%253Dinfo%253Apmid%252F9395249%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0024-3205(97)00881-3\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=9395249\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1997YC07900002\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.18\u0022 data-doi=\u002210.1097\/00005344-200308000-00001\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHuang\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. S.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELeenen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF. H. H\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ. Cardiovasc. Pharmacol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E42\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E153\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E160\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2003\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJournal%2Bof%2Bcardiovascular%2Bpharmacology%26rft.stitle%253DJ%2BCardiovasc%2BPharmacol%26rft.aulast%253DHuang%26rft.auinit1%253DB.%2BS.%26rft.volume%253D42%26rft.issue%253D2%26rft.spage%253D153%26rft.epage%253D160%26rft.atitle%253DSympathoinhibitory%2Band%2Bdepressor%2Beffects%2Bof%2Bamlodipine%2Bin%2Bspontaneously%2Bhypertensive%2Brats.%26rft_id%253Dinfo%253Adoi%252F10.1097%252F00005344-200308000-00001%26rft_id%253Dinfo%253Apmid%252F12883316%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1097\/00005344-200308000-00001\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=12883316\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.19\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESugiyama\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESlow dissociation of long-acting Ca2+ antagonist amlodipine from 3H-PN200-110 binding sites in membranes of rat hearts and brains\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiol. Pharm. Bull\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E19\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E195\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E198\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E1996\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiological%2B%2526%2Bpharmaceutical%2Bbulletin%26rft.stitle%253DBiol%2BPharm%2BBull%26rft.aulast%253DSugiyama%26rft.auinit1%253DK.%26rft.volume%253D19%26rft.issue%253D2%26rft.spage%253D195%26rft.epage%253D198%26rft.atitle%253DSlow%2Bdissociation%2Bof%2Blong-acting%2BCa2%252B%2Bantagonist%2Bamlodipine%2Bfrom%2B3H-PN200-110%2Bbinding%2Bsites%2Bin%2Bmembranes%2Bof%2Brat%2Bhearts%2Band%2Bbrains.%26rft_id%253Dinfo%253Apmid%252F8850304%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=8850304\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.20\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGill\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMendelian randomization for studying the effects of perturbing drug targets\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EWellcome Open Res\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E6\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E16\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DWellcome%2BOpen%2BRes%26rft.volume%253D6%26rft.spage%253D16%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.21\u0022 data-doi=\u002210.1016\/S0140-6736(12)62129-1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-article-title\u0022\u003ECross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E381\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1371\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1379\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%26rft.stitle%253DLancet%26rft.aulast%253DSmoller%2BJW%26rft.volume%253D381%26rft.spage%253D1371%26rft.atitle%253DIdentification%2Bof%2Brisk%2Bloci%2Bwith%2Bshared%2Beffects%2Bon%2Bfive%2Bmajor%2Bpsychiatric%2Bdisorders%253A%2Ba%2Bgenome-wide%2Banalysis.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252812%252962129-1%26rft_id%253Dinfo%253Apmid%252F23453885%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0140-6736(12)62129-1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23453885\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000317894800034\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.22\u0022 data-doi=\u002210.1016\/j.neuropharm.2014.03.021\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStanford\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES. C\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPsychostimulants, antidepressants and neurokinin-1 receptor antagonists (\u2019motor disinhibitors\u2019) have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENeuropharmacology\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E87\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E9\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E18\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNeuropharmacology%26rft.volume%253D87%26rft.spage%253D9%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.neuropharm.2014.03.021%26rft_id%253Dinfo%253Apmid%252F24727210%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.neuropharm.2014.03.021\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24727210\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.23\u0022 data-doi=\u002210.1124\/pr.114.009654\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EZamponi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. W.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStriessnig\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKoschak\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDolphin\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. C.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPharmacol. Rev\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E67\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E821\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E870\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPharmacological%2BReviews%26rft.stitle%253DPharmacol.%2BRev.%26rft.aulast%253DZamponi%26rft.auinit1%253DG.%2BW.%26rft.volume%253D67%26rft.issue%253D4%26rft.spage%253D821%26rft.epage%253D870%26rft.atitle%253DThe%2BPhysiology%252C%2BPathology%252C%2Band%2BPharmacology%2Bof%2BVoltage-Gated%2BCalcium%2BChannels%2Band%2BTheir%2BFuture%2BTherapeutic%2BPotential%26rft_id%253Dinfo%253Adoi%252F10.1124%252Fpr.114.009654%26rft_id%253Dinfo%253Apmid%252F26362469%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/ijlink\/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoicGhhcm1yZXYiO3M6NToicmVzaWQiO3M6ODoiNjcvNC84MjEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyNC8wNS8zMS8yMDI0LjA1LjMwLjI0MzA4MjE2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-ijlink\u0022\u003E\u003Cspan\u003E\u003Cspan class=\u0022cit-reflinks-abstract\u0022\u003EAbstract\u003C\/span\u003E\u003Cspan class=\u0022cit-sep cit-reflinks-variant-name-sep\u0022\u003E\/\u003C\/span\u003E\u003Cspan class=\u0022cit-reflinks-full-text\u0022\u003E\u003Cspan class=\u0022free-full-text\u0022\u003EFREE \u003C\/span\u003EFull Text\u003C\/span\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.24\u0022 data-doi=\u002210.1097\/HJH.0000000000003445\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKerkhofs\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAmlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ. Hypertens\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E41\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1159\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1167\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ.%2BHypertens%26rft.volume%253D41%26rft.spage%253D1159%26rft_id%253Dinfo%253Adoi%252F10.1097%252FHJH.0000000000003445%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1097\/HJH.0000000000003445\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2024.05.30.24308216v1.25\u0022 data-doi=\u002210.1291\/hypres.29.49\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHirooka\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAmlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EHypertens. Res\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E29\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E49\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E56\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2006\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DHypertension%2Bresearch%2B%253A%2B%2Bofficial%2Bjournal%2Bof%2Bthe%2BJapanese%2BSociety%2Bof%2BHypertension%26rft.stitle%253DHypertens%2BRes%26rft.aulast%253DHirooka%26rft.auinit1%253DY.%26rft.volume%253D29%26rft.issue%253D1%26rft.spage%253D49%26rft.epage%253D56%26rft.atitle%253DAmlodipine-induced%2Breduction%2Bof%2Boxidative%2Bstress%2Bin%2Bthe%2Bbrain%2Bis%2Bassociated%2Bwith%2Bsympatho-inhibitory%2Beffects%2Bin%2Bstroke-prone%2Bspontaneously%2Bhypertensive%2Brats.%26rft_id%253Dinfo%253Adoi%252F10.1291%252Fhypres.29.49%26rft_id%253Dinfo%253Apmid%252F16715653%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1291\/hypres.29.49\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=16715653\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000236366200007\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26. in text\u0022 id=\u0022ref-26\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.26\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPark\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.-H.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMitochondria damaged by Oxygen Glucose Deprivation can be Restored through Activation of the PI3K\/Akt Pathway and Inhibition of Calcium Influx by Amlodipine Camsylate\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESci. Rep\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E15717\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSci.%2BRep%26rft.volume%253D9%26rft.spage%253D15717%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E27.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-27-1\u0022 title=\u0022View reference 27. in text\u0022 id=\u0022ref-27\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.27\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDunn\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG. A.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENigg\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. T.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESullivan\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE. L\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ENeuroinflammation as a risk factor for attention deficit hyperactivity disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPharmacol. Biochem. Behav\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E182\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E22\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E34\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPharmacol.%2BBiochem.%2BBehav%26rft.volume%253D182%26rft.spage%253D22%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E28.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-28-1\u0022 title=\u0022View reference 28. in text\u0022 id=\u0022ref-28\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.28\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECorona\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. C\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ERole of Oxidative Stress and Neuroinflammation in Attention-Deficit\/Hyperactivity Disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAntioxidants (Basel\u003C\/abbr\u003E\u003Cem\u003E)\u003C\/em\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E, (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2020\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E29.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-29-1\u0022 title=\u0022View reference 29. in text\u0022 id=\u0022ref-29\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.29\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESveinsd\u00f3ttir\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH. S.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMotility phenotype in a zebrafish vmat2 mutant\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS One\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E17\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003Ee0259753\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2022\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2BOne%26rft.volume%253D17%26rft.spage%253De0259753%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E30.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-30-1\u0022 title=\u0022View reference 30. in text\u0022 id=\u0022ref-30\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.30\u0022 data-doi=\u002210.1038\/nmeth.2019\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchindelin\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EFiji: an open-source platform for biological-image analysis\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Methods\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E9\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E676\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E682\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.stitle%253DNat%2BMethods%26rft.aulast%253DSchindelin%26rft.auinit1%253DJ.%26rft.volume%253D9%26rft.issue%253D7%26rft.spage%253D676%26rft.epage%253D682%26rft.atitle%253DFiji%253A%2Ban%2Bopen-source%2Bplatform%2Bfor%2Bbiological-image%2Banalysis.%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnmeth.2019%26rft_id%253Dinfo%253Apmid%252F22743772%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/nmeth.2019\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=22743772\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000305942200021\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E31.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-31-1\u0022 title=\u0022View reference 31. in text\u0022 id=\u0022ref-31\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.31\u0022 data-doi=\u002210.1038\/s41586-02205473-8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKurki\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM. I.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EFinnGen provides genetic insights from a well-phenotyped isolated population\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENature\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E613\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E508\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E518\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNature%26rft.volume%253D613%26rft.spage%253D508%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41586-02205473-8%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41586-02205473-8\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E32.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-32-1\u0022 title=\u0022View reference 32. in text\u0022 id=\u0022ref-32\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.32\u0022 data-doi=\u002210.1038\/S41588-022-01285-8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDemontis\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EGenome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E55\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E198\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E208\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat.%2BGenet%26rft.volume%253D55%26rft.spage%253D198%26rft_id%253Dinfo%253Adoi%252F10.1038%252FS41588-022-01285-8%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/S41588-022-01285-8\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E33.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-33-1\u0022 title=\u0022View reference 33. in text\u0022 id=\u0022ref-33\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.33\u0022 data-doi=\u002210.1371\/journal.pmed.1001779\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESudlow\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EUK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EPLoS Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E12\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003Ee1001779\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DPLoS%2BMed%26rft.volume%253D12%26rft.spage%253De1001779%26rft_id%253Dinfo%253Adoi%252F10.1371%252Fjournal.pmed.1001779%26rft_id%253Dinfo%253Apmid%252F25826379%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1371\/journal.pmed.1001779\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25826379\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E34.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-34-1\u0022 title=\u0022View reference 34. in text\u0022 id=\u0022ref-34\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.34\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJulkunen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAtlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Commun\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E14\u003C\/span\u003E, \u003Cspan class=\u0022cit-issue\u0022\u003E604\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E35.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-35-1\u0022 title=\u0022View reference 35. in text\u0022 id=\u0022ref-35\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.35\u0022 data-doi=\u002210.1038\/s41588-019-0407-x\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWuttke\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA catalog of genetic loci associated with kidney function from analyses of a million individuals\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E51\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E957\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E972\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat.%2BGenet%26rft.volume%253D51%26rft.spage%253D957%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41588-019-0407-x%26rft_id%253Dinfo%253Apmid%252F31152163%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41588-019-0407-x\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=31152163\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E36.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-36-1\u0022 title=\u0022View reference 36. in text\u0022 id=\u0022ref-36\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.36\u0022 data-doi=\u002210.1093\/bioinformatics\/btab665\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMurphy\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA. E.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESchilder\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EB. M.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESkene\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN. G\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMungeSumstats: A Bioconductor package for the standardisation and quality control of many GWAS summary statistics\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBioinformatics\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E37\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E4593\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E4596\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBioinformatics%26rft.volume%253D37%26rft.spage%253D4593%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fbioinformatics%252Fbtab665%26rft_id%253Dinfo%253Apmid%252F34601555%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/bioinformatics\/btab665\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=34601555\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E37.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-37-1\u0022 title=\u0022View reference 37. in text\u0022 id=\u0022ref-37\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.37\u0022 data-doi=\u002210.1086\/519795\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EPurcell\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EPLINK: a tool set for whole-genome association and population-based linkage analyses\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm. J. Hum. Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E81\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E559\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E575\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2007\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAmerican%2Bjournal%2Bof%2Bhuman%2Bgenetics%26rft.stitle%253DAm%2BJ%2BHum%2BGenet%26rft.aulast%253DPurcell%26rft.auinit1%253DS.%26rft.volume%253D81%26rft.issue%253D3%26rft.spage%253D559%26rft.epage%253D575%26rft.atitle%253DPLINK%253A%2Ba%2Btool%2Bset%2Bfor%2Bwhole-genome%2Bassociation%2Band%2Bpopulation-based%2Blinkage%2Banalyses.%26rft_id%253Dinfo%253Adoi%252F10.1086%252F519795%26rft_id%253Dinfo%253Apmid%252F17701901%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1086\/519795\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=17701901\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E38.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-38-1\u0022 title=\u0022View reference 38. in text\u0022 id=\u0022ref-38\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.38\u0022 data-doi=\u002210.1002\/sim.7221\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBowden\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat. Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E36\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1783\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1802\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStat.%2BMed%26rft.volume%253D36%26rft.spage%253D1783%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fsim.7221%26rft_id%253Dinfo%253Apmid%252F28114746%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/sim.7221\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=28114746\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E39.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-39-1\u0022 title=\u0022View reference 39. in text\u0022 id=\u0022ref-39\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.39\u0022 data-doi=\u002210.1093\/ije\/dyu005\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBurgess\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ESample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt. J. Epidemiol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E43\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E922\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E929\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2014\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInt.%2BJ.%2BEpidemiol%26rft_id%253Dinfo%253Adoi%252F10.1093%252Fije%252Fdyu005%26rft_id%253Dinfo%253Apmid%252F24608958%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1093\/ije\/dyu005\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=24608958\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000338127000037\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E40.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-40-1\u0022 title=\u0022View reference 40. in text\u0022 id=\u0022ref-40\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.40\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHemani\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EG.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe MR-Base platform supports systematic causal inference across the human phenome\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EElife\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E, (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E41.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-41-1\u0022 title=\u0022View reference 41. in text\u0022 id=\u0022ref-41\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.41\u0022 data-doi=\u002210.1038\/s41588-018-0269-7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDemontis\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EDiscovery of the first genome-wide significant risk loci for attention deficit\/hyperactivity disorder\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Genet\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E51\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E63\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E75\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat.%2BGenet%26rft.volume%253D51%26rft.spage%253D63%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fs41588-018-0269-7%26rft_id%253Dinfo%253Apmid%252F30478444%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1038\/s41588-018-0269-7\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=30478444\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E42.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-42-1\u0022 title=\u0022View reference 42. in text\u0022 id=\u0022ref-42\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.42\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGe\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChen\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC.-Y.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFeng\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EY.-C. A.\u003C\/span\u003E\u003C\/span\u003E \u0026amp; \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESmoller\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ. W\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EPolygenic prediction via Bayesian regression and continuous shrinkage priors\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ENat. Commun\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-vol\u0022\u003E10\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E1776\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DNat.%2BCommun%26rft.volume%253D10%26rft.spage%253D1776%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E43.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-43-1\u0022 title=\u0022View reference 43. in text\u0022 id=\u0022ref-43\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2024.05.30.24308216v1.43\u0022 data-doi=\u002210.1186\/s13742-015-0047-8\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EChang\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC. C.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESecond-generation PLINK: rising to the challenge of larger and richer datasets\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EGigascience\u003C\/abbr\u003E \u003Cspan class=\u0022cit-vol\u0022\u003E4\u003C\/span\u003E, \u003Cspan class=\u0022cit-fpage\u0022\u003E7\u003C\/span\u003E (\u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E).\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DGigascience%26rft.volume%253D4%26rft.spage%253D7%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs13742-015-0047-8%26rft_id%253Dinfo%253Apmid%252F25722852%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1186\/s13742-015-0047-8\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=25722852\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2024%2F05%2F31%2F2024.05.30.24308216.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_2xMKaB_ozyQH_X8M4ydhF0QS02D80J6LJ_bdQx4Pl_E.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}